Zim Laboratories Limited
Zim Laboratories Limited (ZIMLAB) financial statements and selected valuation metrics from NSE/BSE exchange filings through 30 June 2026.
Healthcare›Healthcare›Pharmaceuticals & Biotechnology›Pharmaceuticals
zimlab.in(opens the company website in a new tab)Key metrics
Price as of 2026-09-02
Stock price
₹133.95
Market cap
717 Cr
Stock P/E
84.2
P/B
2.23
Dividend yield
0.0%
Sign in for full ratios and TTM. Learn about these metrics →
Share price
NSE closing price from historical market data.
Loading price history…
Statement tables · Consolidated
Switches quarterly, P&L, balance sheet, and cash flow. Key metrics and ratios stay on consolidated when available.
Amounts in ₹ Cr · NSE preferred when both exchanges report the same period · tap + to expand rows
Quarterly results
Quarterly · ₹ Cr · tap + rows to expand
| Metric | Sept 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sept 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sept 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 86 Cr | 96 Cr | 118 Cr | 82 Cr | 92 Cr | 96 Cr | 109 Cr | 72 Cr | 89 Cr | 109 Cr | 105 Cr | 94 Cr |
| Operating expenses (approx.) | 77 Cr | 85 Cr | 102 Cr | 74 Cr | 83 Cr | 85 Cr | 94 Cr | 67 Cr | 83 Cr | 96 Cr | 98 Cr | 92 Cr |
| EBITDA | 9 Cr | 12 Cr | 16 Cr | 8 Cr | 10 Cr | 12 Cr | 15 Cr | 4 Cr | 6 Cr | 13 Cr | 7 Cr | 2 Cr |
| OPM % | 10.9% | 12.0% | 13.3% | 9.8% | 10.3% | 12.0% | 13.4% | 5.9% | 6.5% | 11.8% | 6.8% | 2.6% |
| Other income | 1 Cr | 1 Cr | 2 Cr | 1.00 Cr | 1 Cr | 2 Cr | 2 Cr | 1 Cr | 2 Cr | 2 Cr | 6 Cr | 0.99 Cr |
| Interest | 1 Cr | 2 Cr | 2 Cr | 3 Cr | 3 Cr | 3 Cr | 3 Cr | 3 Cr | 3 Cr | 3 Cr | 3 Cr | 4 Cr |
| Depreciation | 4 Cr | 4 Cr | 4 Cr | 5 Cr | 5 Cr | 5 Cr | 5 Cr | 5 Cr | 5 Cr | 5 Cr | 5 Cr | 5 Cr |
| Profit before tax | 5 Cr | 7 Cr | 11 Cr | 1 Cr | 3 Cr | 6 Cr | 8 Cr | -2 Cr | -0.34 Cr | 6 Cr | 5 Cr | -6 Cr |
| Tax % | 23.8% | 31.8% | 26.5% | 27.2% | 19.6% | 29.9% | 39.8% | 22.9% | -23.5% | 27.3% | 24.3% | 27.9% |
| Net profit | 4 Cr | 5 Cr | 8 Cr | 0.90 Cr | 2 Cr | 4 Cr | 5 Cr | -2 Cr | -0.42 Cr | 4 Cr | 4 Cr | -4 Cr |
| EPS (₹) | ₹0.85 | ₹0.98 | ₹1.66 | ₹0.18 | ₹0.49 | ₹0.82 | ₹1.01 | ₹-0.38 | ₹-0.09 | ₹0.90 | ₹0.76 | ₹-0.75 |
Profit & loss (annual)
Annual · last column is TTM · ₹ Cr · tap + to expand
| Metric | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
|---|---|---|---|---|---|---|---|---|---|
| Sales | 335 Cr | 278 Cr | 307 Cr | 333 Cr | 399 Cr | 367 Cr | 379 Cr | 374 Cr | Sign in for TTM |
| Operating expenses (approx.) | 293 Cr | 255 Cr | 268 Cr | 292 Cr | 347 Cr | 326 Cr | 335 Cr | 344 Cr | Sign in for TTM |
| EBITDA | 42 Cr | 23 Cr | 40 Cr | 41 Cr | 52 Cr | 41 Cr | 44 Cr | 30 Cr | Sign in for TTM |
| OPM % | 12.5% | 8.1% | 12.9% | 12.3% | 13.0% | 11.2% | 11.5% | 8.0% | Sign in for TTM |
| Other income | 2 Cr | 5 Cr | 2 Cr | 4 Cr | 6 Cr | 5 Cr | 6 Cr | 11 Cr | Sign in for TTM |
| Interest | 11 Cr | 13 Cr | 11 Cr | 8 Cr | 6 Cr | 7 Cr | 11 Cr | 13 Cr | Sign in for TTM |
| Depreciation | 11 Cr | 14 Cr | 16 Cr | 16 Cr | 17 Cr | 16 Cr | 20 Cr | 20 Cr | Sign in for TTM |
| Profit before tax | 22 Cr | 0.07 Cr | 10 Cr | 21 Cr | 35 Cr | 24 Cr | 18 Cr | 8 Cr | Sign in for TTM |
| Tax % | 30.5% | -4705.5% | 28.5% | 30.9% | 30.9% | 27.1% | 32.5% | 28.9% | Sign in for TTM |
| Net profit | 15 Cr | 3 Cr | 7 Cr | 15 Cr | 24 Cr | 17 Cr | 12 Cr | 6 Cr | Sign in for TTM |
| EPS (₹) | ₹9.52 | ₹2.03 | ₹4.50 | ₹8.96 | ₹5.01 | ₹3.54 | ₹2.50 | ₹1.19 | Sign in for TTM |
| Dividend payout % | — | — | — | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | Sign in for TTM |
Sign in for TTM
Trailing twelve months totals and margin rows
Balance sheet
Annual · ₹ Cr · tap + rows to expand
| Metric | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|
| Equity capital | 16 Cr | 16 Cr | 16 Cr | 16 Cr | 49 Cr | 49 Cr | 49 Cr | 54 Cr |
| Reserves | 135 Cr | 138 Cr | 145 Cr | 159 Cr | 152 Cr | 190 Cr | 204 Cr | 243 Cr |
| Borrowings | 62 Cr | 77 Cr | 66 Cr | 51 Cr | 60 Cr | 106 Cr | 112 Cr | 123 Cr |
| Other liabilities | 115 Cr | 94 Cr | 98 Cr | 115 Cr | 82 Cr | 102 Cr | 108 Cr | 120 Cr |
| Total liabilities | 328 Cr | 325 Cr | 325 Cr | 342 Cr | 342 Cr | 447 Cr | 472 Cr | 539 Cr |
| Fixed assets (net) | 99 Cr | 107 Cr | 101 Cr | 102 Cr | 104 Cr | 157 Cr | 158 Cr | 156 Cr |
| CWIP | 8 Cr | 5 Cr | 5 Cr | 5 Cr | 18 Cr | 24 Cr | 44 Cr | 59 Cr |
| Investments | 0.05 Cr | 0.05 Cr | 0.05 Cr | 0.05 Cr | 0.05 Cr | 0.05 Cr | 0.05 Cr | 0.05 Cr |
| Loans & advances | 0.25 Cr | 0.16 Cr | 0.08 Cr | 0.02 Cr | 0.05 Cr | 0 Cr | 0 Cr | 0 Cr |
| Inventories | 55 Cr | 56 Cr | 54 Cr | 75 Cr | 54 Cr | 81 Cr | 86 Cr | 94 Cr |
| Trade receivables | 93 Cr | 68 Cr | 72 Cr | 90 Cr | 95 Cr | 100 Cr | 107 Cr | 109 Cr |
| Cash & bank | 0.50 Cr | 1 Cr | 1 Cr | 3 Cr | 6 Cr | 10 Cr | 2 Cr | 25 Cr |
| Other assets | 72 Cr | 87 Cr | 91 Cr | 66 Cr | 65 Cr | 75 Cr | 74 Cr | 96 Cr |
| Total assets | 328 Cr | 325 Cr | 325 Cr | 342 Cr | 342 Cr | 447 Cr | 472 Cr | 539 Cr |
Cash flows
Annual · ₹ Cr · tap + rows to expand · last column includes FCF
| Metric | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|
| Cash from operating activity | — | — | — | 49 Cr | 38 Cr | 16 Cr | 41 Cr | 50 Cr |
| Cash from investing | — | — | — | -15 Cr | -36 Cr | -73 Cr | -40 Cr | -56 Cr |
| Cash from financing | — | — | — | -33 Cr | 0.55 Cr | 60 Cr | -9 Cr | 28 Cr |
| Net cash flow | — | — | — | 2 Cr | 3 Cr | 3 Cr | -8 Cr | 23 Cr |
| Free cash flow (OCF − Capex) | — | — | — | 34 Cr | 0.85 Cr | -58 Cr | 0.36 Cr | 5 Cr |
Ratios
Ratios as reported or derived per annual period.
| Metric | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|
| ROCE % | 15.3% | 5.5% | 9.3% | 12.9% | 15.7% | 8.9% | 8.1% | 5.1% |
| ROE % | 10.2% | 2.1% | 4.3% | 8.3% | 12.2% | 7.2% | 4.8% | 2.0% |
| Debtor days | 101 | 89 | 86 | 98 | 87 | 100 | 103 | 106 |
| Inventory days | 140 | 154 | 129 | 171 | 118 | 167 | 203 | 208 |
| Days payable | 183 | 180 | 155 | 184 | 128 | 128 | 163 | 162 |
| Cash conversion cycle | 58 | 63 | 61 | 85 | 77 | 138 | 143 | 152 |
| Debt / equity | 0.41 | 0.50 | 0.41 | 0.29 | 0.30 | 0.45 | 0.44 | 0.42 |
| Current ratio | 1.27 | 1.30 | 1.35 | 1.45 | 1.72 | 1.43 | 1.39 | 1.45 |
| Net debt / EBITDA | 1.47 | 3.35 | 1.64 | 1.17 | 1.02 | 2.34 | 2.52 | 3.26 |
Compare with peers
Loading peers…